Changing pattern in malignant mesothelioma survival

Translational Oncology

Volumn 8, Issue 1, 2015, Pages 35-39

  Faig, Jennifer ^a   Howard, Suzanne ^b   Levine, Edward A ^b   Casselman, Gary ^c   Hesdorffer, Mary ^d   Ohar, Jill A ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c CCG Inc   (United States)

^d Mesothelioma Applied Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONSTRUCTION WORKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; QUESTIONNAIRE;

EID: 84929933771     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.12.002     Document Type: Article

References (44)

1. Robinson BW and Lake RA (2005). Advances in malignant mesothelioma. N Engl J Med 353(15), 1591–1603
2. Donovan EP, Donovan BL, McKinley MA, Cowan DM, and Paustenbach DJ (2012). Evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature. Crit Rev Toxicol 42(9), 703–731
3. Donovan EP, Donovan BL, Sahmel J, Scott PK, and Paustenbach DJ (2011). Evaluation of bystander exposures to asbestos in occupational settings: a review of the literature and application of a simple eddy diffusion model. Crit Rev Toxicol 41(1), 52–74
4. Ampleford EJ and Ohar J (2007). Mesothelioma: you do not have to work for it. Diagn Cytopathol 35(12), 774–777
5. Roggli VL and Longo WE (1991). Mineral fiber content of lung tissue in patients with environmental exposures: household contacts vs. building occupants. Ann N Y Acad Sci 643, 511–518
6. Anderson HA, Lilis R, Daum SM, Fischbein AS, and Selikoff IF (1976). Household-contact asbestos neoplastic risk. Ann N Y Acad Sci 271, 311–323
7. Magnani C, Agudo A, González CA, Andrion A, Calleja A, Chellini E, Dalmasso P, Escolar A, Hernandez S, and Ivaldi C, et al (2000). Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer 83(1), 104–111
8. Miller A (2005). Mesothelioma in household members of asbestos-exposed workers: 32 United States cases since 1990. Am J Ind Med 47(5), 458–462
9. Browne K and Smither WJ (1983). Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med 40 (2), 145–152
10. Dodson RF, O'Sullivan MF, Huang J, Holiday DB, and Hammar SP (2000). Asbestos in extrapulmonary sites: omentum and mesentery. Chest 117(2), 486–493
11. Dawson A, Gibbs AR, Pooley FD, Griffiths DM, and Hoy J (1993). Malignant mesothelioma in women. Thorax 48(3), 269–274
12. Hyland RA, Ware S, Johnson AR, and Yates DH (2007). Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 33(4), 286–292
13. Skammeritz E, Omland LH, Johansen JP, and Omland O (2011). Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic. Int J Occup Environ Med 2(4), 224–236
14. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, and Trusa S, et al (2011). Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10), 1022–1025
15. Astoul P, Roca E, Galateau-Salle F, and Scherpereel A (2012). Malignant pleural mesothelioma: from the bench to the bedside. Respiration 83(6), 481–493
16. Howlader N, Ries LA, Stinchcomb DG, and Edwards BK (2009). The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst 101(7), 533–536
17. Ohar JA, Ampleford EJ, Howard SE, and Sterling DA (2007). Identification of a mesothelioma phenotype. Respir Med 101(3), 503–509
18. Carbone M, Korb FL, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, and Krausz T, et al (2012). BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10(1), 179
19. Cadby G, Mukherjee S, Musk AW, Reid A, Garlepp M, Dick I, Robinson C, Hui J, Fiorito G, and Guarrera S, et al (2013). A genome-wide association study for malignant mesothelioma risk. Lung Cancer 82(1), 1–8
20. Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, and Russo A, et al (2013). Genetic variants associated with increased risk ofmalignant pleuralmesothelioma: a genome-wide association study. PLoS One 8(4), e61253
21. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Liewehr DJ, Kleiner DE, and Alezander HR (2003). Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21(24), 4560–4567
22. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, and Glehen O (2006). Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13(3), 405–412
23. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, and Levine EA (2001). Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67(10), 999–1003
24. Yan TD, Yoo D, and Sugarbaker PH (2006). Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 32(9), 948–953
25. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, and Sugarbaker PH (2011). A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 117(9), 1855–1863
26. Blackham AU, Shen P, Stewart JH, Russell GB, and Levine EA (2010). Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 17(10), 2720–2727
27. Rice C and Heineman EF (2003). An asbestos job exposure matrix to characterize fiber type, length, and relative exposure intensity. Appl Occup Environ Hyg 18(7), 506–512
28. Munkholm-Larsen S, Cao CQ, and Yan TD (2009). Malignant peritoneal mesothelioma. World J Gastrointest Surg 1(1), 38–48
29. Al-Quteimat O and Al-Badaineh M (2013). Intraperitoneal chemotherapy: Rationale, applications, and limitations. J Oncol Pharm Pract, 1–12
30. Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, and Richards WG (2013). Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 145(4), 955–963
31. Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, and Bueno R, et al (2009). Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138(2), 405–411
32. Kodama K, Higashiyama M, Okami J, Tokunaga T, Fujiwara A, Imamura F, and Nakayama T (2013). Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy. Int J Hyperthermia 29(7), 653–662
33. Tsao AS, Wistuba I, Roth JA, and Kindler HL (2009). Malignant pleural mesothelioma. J Clin Oncol 27(12), 2081–2090
34. Haas AR and Sterman DH (2013). Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med 34(1), 99–111
35. Zauderer M and Krug LM (2011). The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol, 163–172
36. Haber SE and Haber JM (2011). Malignant mesothelioma: a clinical study of 238 cases. Ind Health 49(2), 166–172
37. Kanarek MS (2014). Mesothelioma from chrysotile asbestos: update. J Ann Epidemiol, 688–697
38. American Thoracic Society (2004). Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 170(6), 691–715
39. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, and Gaudino G (2013). BAP1 and cancer. Nat Rev Cancer 13(3), 153–159
40. Huncharek M, Kelsey K, Muscat J, and Christiani D (1996). Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study. Cancer Lett 102(1–2), 205–208
41. Heineman EF, Bernstein L, Stark AD, and Spirtas R (1996). Mesothelioma, asbestos, and reported history of cancer in first-degree relatives. Cancer 77(3), 549–554
42. Hillerdal G (1999). Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 56(8), 505–513
43. Metintas S, Metintas M, Ucgun I, and Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 122(6), 2224–2229
44. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, and Wolf I, et al (2011). Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10), 1018–1021.